Illuminating cytochrome P450 binding: Ru(II)-caged inhibitors of CYP17A1

被引：59

作者：

Li, Ao ^{[1
]}

Yadav, Rahul ^{[2
]}

White, Jessica K. ^{[3
]}

Herroon, Mackenzie K. ^{[4
]}

Callahan, Brian P. ^{[5
]}

Podgorski, Izabela ^{[4
,6
]}

Turro, Claudia ^{[3
]}

Scott, Emily E. ^{[2
]}

Kodanko, Jeremy J. ^{[1
,6
]}

机构：

[1] Wayne State Univ, Dept Chem, Detroit, MI 48202 USA

[2] Univ Michigan, Dept Med Chem, Ann Arbor, MI 48109 USA

[3] Ohio State Univ, Dept Chem & Biochem, Columbus, OH 43210 USA

[4] Wayne State Univ, Sch Med, Dept Pharmacol, Detroit, MI 48201 USA

[5] Binghamton Univ, Dept Chem, Binghamton, NY 13902 USA

[6] Barbara Ann Karmanos Canc Inst, Detroit, MI 48201 USA

来源：

CHEMICAL COMMUNICATIONS | 2017年 / 53卷 / 26期

基金：

美国国家科学基金会; 美国国家卫生研究院;

关键词：

PROSTATE-CANCER; VISIBLE-LIGHT; RUTHENIUM(II) COMPLEX; P450; INHIBITORS; CELL-LINES; ABIRATERONE; LIGANDS; 17A1;

D O I：

10.1039/c7cc01459g

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

New Ru(II)-caged abiraterone complexes were synthesized that exhibit strong absorption in the visible region and release the steroidal CYP17A1 inhibitor abiraterone upon exposure to low energy visible light in buffer and prostate cancer cells. Photoinduced release results in abiraterone binding to its CYP17A1 target in an inhibitory mode.

引用

页码：3673 / 3676

页数：4

共 50 条

[31] Cytochrome P450 CYP1 overexpression in human tumors
Androutsopoulos, Vasilis
Sifakis, Stavros
Alegakis, Athanasios
Kiriakakis, Michalis
Ploumidis, Achilles
Vakonaki, Elena
Delakas, Dimitris
Spandidos, Demetrios
Tsatsakis, Aristidis
TOXICOLOGY LETTERS, 2012, 211 : S54 - S54
[32] Structure-Based Design of Inhibitors with Improved Selectivity for Steroidogenic Cytochrome P450 17A1 over Cytochrome P450 21A2
Fehl, Charlie
Vogt, Caleb D.
Yadav, Rahul
Li, Kelin
Scott, Emily E.
Aube, Jeffrey
JOURNAL OF MEDICINAL CHEMISTRY, 2018, 61 (11) : 4946 - 4960
[33] THE EFFECTS OF CYTOCHROME P450 (CYP) INHIBITORS ON ORAL METHADONE IN GREYHOUND DOGS.
KuKanich, Butch
KuKanich, Kate Stenske
Rodriguez, Jessica
JOURNAL OF VETERINARY INTERNAL MEDICINE, 2011, 25 (03) : 741 - 741
[34] Effective Cytochrome P450 (CYP) Inhibitors Isolated from Tarragon (Artemisia dracunculus)
Brahmi, Zeineb
Katho, Tatsuya
Hatsumata, Rie
Hiroi, Asako
Miyakawa, Nami
Yakou, Emi
Sugaya, Kouichi
Onose, Jun-ichi
Abe, Naoki
BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY, 2012, 76 (05) : 1028 - 1031
[35] Conformational selection dominates binding of steroids to human cytochrome P450 17A1
Guengerich, F. Peter
Wilkey, Clayton J.
Glass, Sarah M.
Reddish, Michael J.
JOURNAL OF BIOLOGICAL CHEMISTRY, 2019, 294 (26) : 10028 - 10041
[36] Molecular evolution of Cytochrome P450 (CYP) genes
Kawashima, Ayaka
GENES & GENETIC SYSTEMS, 2013, 88 (06) : 368 - 368
[37] Role of cytochrome P450 (CYP) in dopamine formation
Bromek, E
Haduch, A
Daniel, WA
PHARMACOLOGICAL REPORTS, 2006, 58 (02) : 313 - 314
[38] Ethynyl and Propynylpyrene Inhibitors of Cytochrome P450
Zhu, Naijue
Lightsey, Danielle
Liu, Jiawang
Foroozesh, Maryam
Morgan, Kathleen M.
Stevens, Edwin D.
Stevens, Cheryl L. Klein
JOURNAL OF CHEMICAL CRYSTALLOGRAPHY, 2010, 40 (04) : 343 - 352
[39] In silico prediction of cytochrome P450 inhibitors
Refsgaard, Hanne H. F.
Jensen, Berith F.
Christensen, Inge Thoger
Hagen, Nina
Brockhoff, Per B.
DRUG DEVELOPMENT RESEARCH, 2006, 67 (05) : 417 - 429
[40] Loss of Cytochrome P450 17A1 Protein Expression in a 17α-Hydroxylase/17,20-Lyase-Deficient 46,XY Female Caused by Two Novel Mutations in the CYP17A1 Gene
Nayelli Nájera
Nayely Garibay
Yadira Pastrana
Icela Palma
Yolanda-Rocio Peña
Javier Pérez
Ninel Coyote
Alberto Hidalgo
Susana Kofman-Alfaro
Gloria Queipo
Endocrine Pathology, 2009, 20 : 249 - 255

← 1 2 3 4 5 →